A Double-Blind, Randomized, Placebo-Controlled, Multiple Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-64565111 in Men and Women With Type 2 Diabetes Mellitus
Phase of Trial: Phase I
Latest Information Update: 17 Apr 2018
At a glance
- Drugs HM 12525A (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Janssen Research & Development
- 31 Aug 2018 Biomarkers information updated
- 11 Apr 2018 Status changed from recruiting to completed.
- 19 Jan 2018 Planned End Date changed from 5 Jan 2018 to 19 Feb 2018.